Page last updated: 2024-12-06

toloxatone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Toloxatone is a medication used to treat major depressive disorder. It is a selective serotonin reuptake inhibitor (SSRI) that is also thought to have effects on other neurotransmitters, such as norepinephrine and dopamine. Toloxatone is thought to work by increasing the levels of serotonin in the brain, which is a neurotransmitter that plays a role in mood regulation. The mechanism of action of Toloxatone, which is poorly understood, has been suggested to involve the inhibition of the reuptake of serotonin, norepinephrine, and dopamine, the antagonism of 5-HT1A and 5-HT2A receptors, and the inhibition of monoamine oxidase A (MAO-A). It has been reported to produce antidepressant effects within 1-2 weeks of initiation of treatment. Toloxatone was first synthesized by researchers at the Swiss pharmaceutical company Sandoz in the 1970s. Toloxatone is a relatively new antidepressant and is being studied to see how effective it is in treating other conditions, such as anxiety disorders. It is also being studied to see if it can be used to help people with chronic pain.'

toloxatone: oxazolidinone derivative; psychotropic drug; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

toloxatone : A racemate consisting of equimolar amounts of (R)- and (S)-toloxatone. It is a reversible monoamine oxidase A inhibitor and antidepressant. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one : A member of the class of oxazolidinones that is 5-(hydroxymethyl)-1,3-oxazolidin-2-one substituted by a 3-methylphenyl group at position 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID34521
CHEMBL ID18116
CHEBI ID156575
SCHEMBL ID49437
MeSH IDM0056580

Synonyms (60)

Synonym
humoryl
md-69276
umoril
perenum
D02559
29218-27-7
humoryl (tn)
toloxatone (inn)
5-(hydroxymethyl)-3-m-tolyl-2-oxazolidinone
toloxatone [inn]
5-hydroxymethyl-3-(m-tolyl)-2-oxazolidinone
delalande 69276
69276 md
5-(hydroxymethyl)-3-(3-methylphenyl)-2-oxazolidinone
2-oxazolidinone, 5-hydroxymethyl-3-(m-tolyl)-
einecs 249-522-2
brn 0527506
toloxatonum [inn-latin]
toloxatona [inn-spanish]
toloxatone
5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one
CHEBI:156575
CHEMBL18116 ,
taloxotone
bdbm50110725
5-(hydroxymethyl)-3-(3-methylphenyl)-oxazolidin-2-one
5-hydroxymethyl-3-m-tolyl-oxazolidin-2-one
2-oxazolidinone, 5-(hydroxymethyl)-3-(3-methylphenyl)-
AKOS016014000
toloxatonum
5t206015t5 ,
toloxatona
unii-5t206015t5
FT-0630548
2-oxazolidinone,5-(hydroxymethyl)-3-(3-methylphenyl)-
(+/-)-5-(hydroxymethyl)-3-m-tolyl-2-oxazolidinone
toloxatone [mart.]
toloxatone [mi]
toloxatone [who-dd]
SCHEMBL49437
5-(hydroxymethyl)-3-(m-tolyl)oxazolidin-2-one ,
DB09245
5-(hydroxymethyl)-3-m-tolyloxazolidin-2-one
SR-01000944934-1
sr-01000944934
toloxatone, >=98% (hplc), solid
J-017439
DTXSID40865478
Q3530618
Z1509617301
AS-16848
toloxatone (md 69276)
md 69276; md-69276; md69276
BCP32681
CS-0002916
D84133
md 69276
HY-14196
S0160
EN300-6745454

Research Excerpts

Overview

Toloxatone is a new monoamine oxidase inhibitor.

ExcerptReferenceRelevance
"Toloxatone is a new monoamine oxidase inhibitor. "( [Acute toloxatone poisoning. Apropos of 122 cases].
Azoyan, P; Baud, FJ; Efthymiou, ML; Garnier, R,
)
2.03

Pharmacokinetics

Toloxatone was cleared from plasma with a half-life (t 1/2 beta) of 0.1%. This pharmacodynamic interaction could be explained by an increase in tyramine systemic bioavailability in the presence of toloxatones.

ExcerptReferenceRelevance
" No differences were observed in the pharmacokinetic parameters with the increase of the dose."( Toloxatone pharmacokinetics in the plasma and cerebrospinal fluid of the rabbit.
Lamiable, D; Leon, A; Vistelle, R; Wiczewski, M; Zinsou, M, 1992
)
1.73
" This pharmacodynamic interaction could be explained by an increase in tyramine systemic bioavailability in the presence of toloxatone."( Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects.
D'Estanque, J; Ego, D; Funck-Brentano, C; Jaillon, P; Provost, JC; Rovei, V, 1992
)
0.74
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
" This pharmacodynamic interaction could be explained by an increase in tyramine systemic bioavailability in the presence of toloxatone."( Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects.
D'Estanque, J; Ego, D; Funck-Brentano, C; Jaillon, P; Provost, JC; Rovei, V, 1992
)
0.74
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
toluenesAny member of the class of benzenes that is a substituted benzene in which the substituents include one (and only one) methyl group.
oxazolidinoneAn oxazolidine containing one or more oxo groups.
primary alcoholA primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Amine oxidase [flavin-containing] A Rattus norvegicus (Norway rat)IC50 (µMol)3.26000.00071.979812.5000AID1459901
Amine oxidase [flavin-containing] A Rattus norvegicus (Norway rat)Ki0.38000.00190.55334.8000AID238291
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)2.84790.00002.37899.7700AID1152188; AID1158610; AID1192163; AID1261175; AID1278146; AID1297407; AID1373671; AID1409019; AID1432427; AID1484646; AID1498689; AID1498695; AID1512062; AID1514580; AID1571214; AID1624337; AID1891688; AID1896381; AID1917481
Amine oxidase [flavin-containing] AHomo sapiens (human)Ki1.50000.00192.379710.0000AID751392
Amine oxidase [flavin-containing] A Bos taurus (cattle)IC50 (µMol)0.38020.00290.10380.3802AID277618; AID367003
Amine oxidase [flavin-containing] A Bos taurus (cattle)Ki0.85330.00251.35733.8000AID125546; AID377654; AID641691
Amine oxidase [flavin-containing] BHomo sapiens (human)IC50 (µMol)80.00000.00001.89149.5700AID1571215
Amine oxidase [flavin-containing] BHomo sapiens (human)Ki15.00000.00061.777110.0000AID238322
Amine oxidase [flavin-containing] BBos taurus (cattle)IC50 (µMol)15.13561.00001.00001.0000AID277619; AID367273
Amine oxidase [flavin-containing] BBos taurus (cattle)Ki15.00000.05401.83906.0000AID126506; AID641692
Amine oxidase [flavin-containing] BMus musculus (house mouse)IC50 (µMol)3.92000.00001.50673.9200AID1512062
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
catecholamine metabolic processAmine oxidase [flavin-containing] A Bos taurus (cattle)
response to xenobiotic stimulusAmine oxidase [flavin-containing] BHomo sapiens (human)
response to toxic substanceAmine oxidase [flavin-containing] BHomo sapiens (human)
response to aluminum ionAmine oxidase [flavin-containing] BHomo sapiens (human)
response to selenium ionAmine oxidase [flavin-containing] BHomo sapiens (human)
negative regulation of serotonin secretionAmine oxidase [flavin-containing] BHomo sapiens (human)
phenylethylamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
substantia nigra developmentAmine oxidase [flavin-containing] BHomo sapiens (human)
response to lipopolysaccharideAmine oxidase [flavin-containing] BHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to ethanolAmine oxidase [flavin-containing] BHomo sapiens (human)
positive regulation of dopamine metabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
hydrogen peroxide biosynthetic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to corticosteroneAmine oxidase [flavin-containing] BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] A Bos taurus (cattle)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] A Bos taurus (cattle)
monoamine oxidase activityAmine oxidase [flavin-containing] A Bos taurus (cattle)
protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
electron transfer activityAmine oxidase [flavin-containing] BHomo sapiens (human)
identical protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BBos taurus (cattle)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BBos taurus (cattle)
monoamine oxidase activityAmine oxidase [flavin-containing] BBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] A Bos taurus (cattle)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial envelopeAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] BHomo sapiens (human)
dendriteAmine oxidase [flavin-containing] BHomo sapiens (human)
neuronal cell bodyAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BBos taurus (cattle)
mitochondrial outer membraneAmine oxidase [flavin-containing] BBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (78)

Assay IDTitleYearJournalArticle
AID1432427Inhibition of recombinant human MAO-A using kynuramine as substrate incubated for 10 mins2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
Selective inhibition of monoamine oxidase A by purpurin, an anthraquinone.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1158610Inhibition of recombinant human MAO-A expressed in insect cells assessed as inhibition of oxidation of kynuramine to 4-hydroxyquinoline after 20 mins by fluorescence spectrophotometry2014European journal of medicinal chemistry, Jul-23, Volume: 82New insights into the biological properties of Crocus sativus L.: chemical modifications, human monoamine oxidases inhibition and molecular modeling studies.
AID1891688Inhibition of human recombinant MAOA using kynuramine substrate incubated for 20 mins by fluorescence spectrophotometry2022Bioorganic & medicinal chemistry letters, 07-01, Volume: 67The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID234965Selectivity for MAO-B over MAO-A2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
3-(1H-Pyrrol-1-yl)-2-oxazolidinones as reversible, highly potent, and selective inhibitors of monoamine oxidase type A.
AID367003Inhibition of bovine mitochondrial MAOA2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis, molecular modeling studies and selective inhibitory activity against MAO of N1-propanoyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID468443Inhibition of human FAAH at 1 uM2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
AID1571215Inhibition of MAOB (unknown origin) using benzylamine as substrate preincubated for 30 mins followed by substrate addition2018MedChemComm, Nov-01, Volume: 9, Issue:11
Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1373678Inhibition of human recombinant MAOA assessed as residual enzyme activity at 2 uM pre-incubated for 30 mins followed by 0.06 mM kynuramine substrate addition2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Selective inhibition of monoamine oxidase A by hispidol.
AID277620Selectivity index, pIC50 for MAO-A/pIC50 for MAO-B2007Journal of medicinal chemistry, Feb-08, Volume: 50, Issue:3
Monoamine oxidase isoform-dependent tautomeric influence in the recognition of 3,5-diaryl pyrazole inhibitors.
AID641693Selectivity index, ratio of Ki for bovine MAOB to Ki for bovine MAOA2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Novel reversible monoamine oxidase A inhibitors: highly potent and selective 3-(1H-pyrrol-3-yl)-2-oxazolidinones.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1624340Competitive inhibition of human recombinant MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 20 mins by Lineweaver-Burk plot analysis2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Osthenol, a prenylated coumarin, as a monoamine oxidase A inhibitor with high selectivity.
AID1498695Reversible inhibition of recombinant human MAO-A assessed as residual activity using kynuramine as substrate preincubated for 30 mins followed by dialysis for 6 hrs by spectrophotometric method2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Selective inhibition of monoamine oxidase A by chelerythrine, an isoquinoline alkaloid.
AID277619Inhibition of MAO-B in bovine brain mitochondria fluorimetric method2007Journal of medicinal chemistry, Feb-08, Volume: 50, Issue:3
Monoamine oxidase isoform-dependent tautomeric influence in the recognition of 3,5-diaryl pyrazole inhibitors.
AID238322Inhibitory concentration for human Monoamine oxidase B2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Design, synthesis, and biological activities of pyrrolylethanoneamine derivatives, a novel class of monoamine oxidases inhibitors.
AID1373679Reversible inhibition of human recombinant MAOA assessed as residual enzyme activity at 2 uM pre-incubated with enzyme for 30 mins followed by dialysis with pH 7.2 sodium phosphate buffer for 6 hrs followed by 0.06 mM kynuramine substrate addition2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Selective inhibition of monoamine oxidase A by hispidol.
AID377654Inhibition of bovine MAO-A by fluorimetric method2006Journal of natural products, Jun, Volume: 69, Issue:6
Quercetin as the active principle of Hypericum hircinum exerts a selective inhibitory activity against MAO-A: extraction, biological analysis, and computational study.
AID1624338Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI insect cells using benzylamine as substrate after 30 mins by spectrophotometric analysis2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Osthenol, a prenylated coumarin, as a monoamine oxidase A inhibitor with high selectivity.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID277618Inhibition of MAO-A in bovine brain mitochondria by fluorimetric method2007Journal of medicinal chemistry, Feb-08, Volume: 50, Issue:3
Monoamine oxidase isoform-dependent tautomeric influence in the recognition of 3,5-diaryl pyrazole inhibitors.
AID1624351Reversible inhibition of human recombinant MAO-A expressed in baculovirus infected BTI insect cells assessed as residual activity at 2 uM incubated for 30 mins using kynuramine as substrate by spectrophotometric analysis relative to control2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Osthenol, a prenylated coumarin, as a monoamine oxidase A inhibitor with high selectivity.
AID1571221Reversible inhibition of MAOA (unknown origin) assessed as residual enzyme activity at 2 uM using kynuramine as substrate measured after 30 mins relative to control2018MedChemComm, Nov-01, Volume: 9, Issue:11
Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1152189Inhibition of recombinant human MAO-B using kynuramine as substrate assessed as 4-hydroxyquinoline production after 30 mins by fluorescence spectrophotometry analysis2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
α-Tetralone derivatives as inhibitors of monoamine oxidase.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1624337Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 20 mins by spectrophotometric analysis2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Osthenol, a prenylated coumarin, as a monoamine oxidase A inhibitor with high selectivity.
AID1917481Inhibition of human recombinant MAO-A assessed as inhibition of 4-hydroxyquinoline formation using kynuramine as substrate incubated for 20 mins by fluorescence spectrophotometry2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Isatoic anhydrides as novel inhibitors of monoamine oxidase.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1498693Inhibition of recombinant human MAO-A assessed as residual activity at 1.1 uM using kynuramine as substrate after 30 mins by spectrophotometric method relative to control2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Selective inhibition of monoamine oxidase A by chelerythrine, an isoquinoline alkaloid.
AID1261175Inhibition of human MAO-A expressed in baculovirus infected BT1 cells microsome fraction by fluorescence spectrometry2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Monoamine oxidase inhibitory activities of heterocyclic chalcones.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1192163Inhibition of human recombinant MAO-A assessed as kynuramine oxidation to 4-hydroxyquinoline formation by spectrofluorometric analysis2015Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6
Inhibition of monoamine oxidase by indole-5,6-dicarbonitrile derivatives.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1152188Inhibition of recombinant human MAO-A using kynuramine as substrate assessed as 4-hydroxyquinoline production after 30 mins by fluorescence spectrophotometry analysis2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
α-Tetralone derivatives as inhibitors of monoamine oxidase.
AID1459901Inhibition of Sprague-Dawley rat brain MAO-A using [14C]5-HT as substrate preincubated for 20 mins followed by substrate addition measured after 5 mins by scintillation spectrometry2017European journal of medicinal chemistry, Jan-05, Volume: 125Benzyloxynitrostyrene analogues - A novel class of selective and highly potent inhibitors of monoamine oxidase B.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID367273Inhibition of bovine mitochondrial MAOB2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis, molecular modeling studies and selective inhibitory activity against MAO of N1-propanoyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID751392Inhibition of MAO-A (unknown origin) by luciferase reporter gene assay2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
Recent development of potent analogues of oxazolidinone antibacterial agents.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID244288Selectivity for rat Monoamine oxidase A as ratio of Ki(MAO-B)/Ki(MAO-A)2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Design, synthesis, and biological activities of pyrrolylethanoneamine derivatives, a novel class of monoamine oxidases inhibitors.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1409019Inhibition of recombinant human MAO-A using kynuramine as substrate after 20 mins by fluorescence spectrophotometric analysis2018Bioorganic & medicinal chemistry, 11-01, Volume: 26, Issue:20
Synthesis and evaluation of 2-substituted 4(3H)-quinazolinone thioether derivatives as monoamine oxidase inhibitors.
AID1571222Reversible inhibition of MAOA (unknown origin) assessed as residual enzyme activity at 2 uM using kynuramine as substrate pre-incubated for 30 mins followed by dialysis with pH 7.2 sodium phosphate buffer relative to control2018MedChemComm, Nov-01, Volume: 9, Issue:11
Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors.
AID1297407Inhibition of human recombinant MAO-A using kynuramine as substrate incubated for 20 mins by fluorescence spectrophotometric analysis2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
An evaluation of synthetic indole derivatives as inhibitors of monoamine oxidase.
AID641691Inhibition of bovine brain MAOA using kynuramine as a substrate after 30 mins by spectrofluorometric method2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Novel reversible monoamine oxidase A inhibitors: highly potent and selective 3-(1H-pyrrol-3-yl)-2-oxazolidinones.
AID1571216Selectivity index, ratio of IC50 for MAOA (unknown origin) to IC50 for MAOB (unknown origin)2018MedChemComm, Nov-01, Volume: 9, Issue:11
Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors.
AID238291Inhibitory concentration for rat Monoamine oxidase A2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Design, synthesis, and biological activities of pyrrolylethanoneamine derivatives, a novel class of monoamine oxidases inhibitors.
AID641692Inhibition of bovine brain MAOB using kynuramine as a substrate after 30 mins by spectrofluorometric method2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Novel reversible monoamine oxidase A inhibitors: highly potent and selective 3-(1H-pyrrol-3-yl)-2-oxazolidinones.
AID1484646Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cell microsomes using kynuramine as substrate after 20 mins by fluorescence spectroscopy2017European journal of medicinal chemistry, Jul-28, Volume: 135The evaluation of 1,4-benzoquinones as inhibitors of human monoamine oxidase.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1192164Inhibition of human recombinant MAO-B assessed as kynuramine oxidation to 4-hydroxyquinoline formation by spectrofluorometric analysis2015Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6
Inhibition of monoamine oxidase by indole-5,6-dicarbonitrile derivatives.
AID1624352Reversible inhibition of human recombinant MAO-A expressed in baculovirus infected BTI insect cells assessed as residual activity at 2 uM incubated for 30 mins followed by dialysis using kynuramine as substrate by spectrophotometric analysis relative to c2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Osthenol, a prenylated coumarin, as a monoamine oxidase A inhibitor with high selectivity.
AID126506Inhibition of bovine brain mitochondrial Monoamine oxidase B (MAO-B) compared to toloxatone2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
3-(1H-Pyrrol-1-yl)-2-oxazolidinones as reversible, highly potent, and selective inhibitors of monoamine oxidase type A.
AID1278146Inhibition of recombinant human MAO-A after 20 mins using 50 uM kynuramine as substrate by fluorescence spectrophotometry2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Inhibition of monoamine oxidase by benzoxathiolone analogues.
AID1512062Inhibition of human recombinant MAO-A expressed in insect cells microsomes assessed as inhibition of 4-hydroxyquinoline formation using kynuramine as substrate incubated for 20 mins by fluorescence spectrophotometry analysis2019Bioorganic & medicinal chemistry letters, 11-01, Volume: 29, Issue:21
1,3,4-Oxadiazol-2-ylbenzenesulfonamides as privileged structures for the inhibition of monoamine oxidase B.
AID1498694Reversible inhibition of recombinant human MAO-A assessed as residual activity at 1.1 uM using kynuramine as substrate preincubated for 30 mins followed by dialysis for 6 hrs by spectrophotometric method relative to control2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Selective inhibition of monoamine oxidase A by chelerythrine, an isoquinoline alkaloid.
AID1896381Inhibition of recombinant human MAO-A using using kynuramine as substrate assessed as inhibition of 4-hydroxyquinoline formation incubated for 20 mins by fluorescence spectrophotometric analysis2022Bioorganic & medicinal chemistry letters, Dec-01, Volume: 77The inhibition of monoamine oxidase by 2H-1,4-benzothiazin-3(4H)-ones.
AID125546Inhibition of bovine brain mitochondrial Monoamine oxidase A (MAO-A) compared to toloxatone2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
3-(1H-Pyrrol-1-yl)-2-oxazolidinones as reversible, highly potent, and selective inhibitors of monoamine oxidase type A.
AID1192165Selectivity index, ratio of IC50 for human recombinant MAO-B to IC50 for human recombinant MAO-A2015Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6
Inhibition of monoamine oxidase by indole-5,6-dicarbonitrile derivatives.
AID1571214Inhibition of MAOA (unknown origin) using kynuramine as substrate preincubated for 30 mins followed by substrate addition2018MedChemComm, Nov-01, Volume: 9, Issue:11
Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors.
AID1373671Inhibition of human recombinant MAOA using kynuramine as substrate preincubated for 30 mins followed by substrate addition2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Selective inhibition of monoamine oxidase A by hispidol.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1498689Inhibition of recombinant human MAO-A using kynuramine as substrate incubated for 20 mins by spectrophotometric method2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Selective inhibition of monoamine oxidase A by chelerythrine, an isoquinoline alkaloid.
AID1514580Inhibition of recombinant human MAOA expressed in insect cell microsomes using kynuramine as substrate measured after 20 mins by fluorescence spectrophotometry2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Novel monoamine oxidase inhibitors based on the privileged 2-imidazoline molecular framework.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (54)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (22.22)18.7374
1990's12 (22.22)18.2507
2000's9 (16.67)29.6817
2010's18 (33.33)24.3611
2020's3 (5.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.96 (24.57)
Research Supply Index4.20 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index44.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (10.00%)5.53%
Reviews3 (5.00%)6.00%
Case Studies3 (5.00%)4.05%
Observational0 (0.00%)0.25%
Other48 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]